A 6-month, Multicenter, single-Arm, observational study with a 6-month extension evaluating patient-reported outcomes of insulin Glargine 300 U/mL (Gla-300) in
basal/bolus-treated people with T2 diabetes on therapy in a rEal world setting (MAGE study) (PRO of Insulin Glargine 300 U/mL in T2 diabetes in)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  Prospective patient-based data collection

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No